DOCSLIB.ORG

©Ferrata Storti Foundation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
©Ferrata Storti Foundation Stem Cell Transplantation • Research Paper Extracorporeal chemophototherapy for the treatment of graft-versus-host disease: hematologic consequences of short-term, intensive courses Frédéric Garban Background and Objectives. Extracorporeal chemophototherapy (ECP) is considered an Philippe Drillat immunomodulatory agent useful in both acute and chronic graft-versus-host disease Caroline Makowski (GVHD). Little is known about the best treatment schedule, and there are no data con- Marie-Christine Jacob cerning hematologic parameters and cellular compositions of products during the treat- Marie-Jeanne Richard ment. Marie Favrot Jean Jacques Sotto Design and Methods. This was a single-center study of 27 patients treated with ECP Jean Claude Bensa for corticoresistant GVHD. Treatment was given in a short-term series of six courses Jean Yves Cahn over 3 weeks, and in case of response, consolidation treatment was given until com- plete response or stabilization of lesions. Results. Nine out of 12 patients with acute GVHD responded to treatment. In patients with chronic GVHD, 13 out of 15 patients responded (11 complete and 2 partial responses). Responses were obtained essentially in skin or gut lesions; ECP was of particular effect in three cases of bronchiolitis obliterans associated with transplanta- tion, with all three patients responding. Hematologic consequences were studied in patients with chronic GVHD: hemoglobin levels increased significantly after treatment and a reduction in red blood cell transfusion requirements was also observed. Interpretations and Conclusions. ECP is effective in both chronic and acute GVHD, par- ticularly in lung forms. ECP can reduce the duration of immunosuppressive therapy and improve erythroid recovery. ECP product quality, including standardization for the num- ber of mononuclear cells for each patient, needs further investigation. Key words: extracorporeal chemophototherapy, graft-versus-host disease, intensive courses. Haematologica 2005; 90:1096-1101 ©2005 Ferrata Storti Foundation From the Département de 5 cancérologie et d’hématologie, llogeneic stem cell transplantation Sézary’s lymphoma and later to treat graft CHU de Grenoble BP 217 38043 can create a conflict between the rejection in organ transplantation,6 as an Grenoble France & INERM 0353 Aimmune systems of the donor and immunomodulating strategy in other Institut A. Bonniot, Faculté de the host. A strong anti-malignancy effect immunological disorders involving T Médecine de Grenoble 38706 La (GVM effect) results from this conflict as cells7,8 and in type 1 diabetes.9 ECP has Tronche France (FG, CM, JJS, JYC); 10 Etablissement Français du Sang, does an immunological complication been successfully used to treat both acute avenue du Maquis du Grésivaudan called graft-versus-host disease (GVHD). and chronic forms of GVHD.11-14 Several 38700 La tronche France (PD, Despite progress in the management of studies both in children15 and adults12 sug- M-CJ, JCB); Unité mixte de thérapie patients who receive transplants, GVHD gest that ECP is effective either in combi- cellulaire, CHU de Grenoble BP 217 remains one of the major causes of non- nation with other immunosuppressive 38043 Grenoble France (M-JR, MF). relapse mortality.1,2 GVHD principally drugs or alone in steroid-resistant Correspondence: affects the skin, gut and liver in its acute GVHD.10 However, little is known about Frédéric Garban, MD, PhD, form, whereas chronic GVHD has various the optimal conditions for conducting Departement de Cancerologie et clinical manifestations among which apheresis and the schedule that could be d’Hématologie, CHU de Grenoble cytopenia is frequent and anemia may applied to patients. The best mononuclear BP217, 38043 Grenoble, France. E-mail: frederic.garban@ujf-greno- require blood transfusion. Various thera- cell dose to use for clinical benefit is ble.fr pies have been proposed for the treatment unknown. As previously reported, ECP is of patients with GVHD, such as a well-tolerated procedure that could be cyclosporine, tacrolimus, mycophenolate an alternative treatment with the aim of mofetil, monoclonal antibodies and corti- avoiding some of the hematologic and costeroids.3 All these approaches lead to immune complications of conventional prolonged immunosuppression and an therapies for GVHD. increased risk of infectious complications.4 Here we report our single-center experi- Extracorporeal chemophototherapy (ECP) ence with 27 consecutive patients treated was initially used successfully to treat for acute or chronic GVHD, with an inten- | 1096 | haematologica/the hematology journal | 2005; 90(8) Extracorporeal chemophototherapy for GVHD sive, promptly instituted series of courses of ECP. We Table 1. General characteristics of the patients treated with ECP. explored the consequences of this treatment on hematologic parameters and the composition of the cell product infused into the patients. Acute GVHD Chronic GVHD N 12 15 Design and Methods Age 40 (23–63) 45 ( 14–62) Patients Diagnosis Acute leukemia 7 2 This was a pilot study based on 7 years of experi- Chronic myeloid leukemia 2 5 ence (1997-2004) with the use of ECP. Twenty-seven Multiple myeloma 1 4 Myelodysplastic syndrome 2 adult patients were treated for acute (12 patients) or Myeloproliferative disease 1 chronic GVHD (15 patients). All patients gave their Fanconi’s anemia 1 informed consent. Diagnosis was assessed by skin, Solid tumor 1 gut or liver biopsies. Lung disease was explored by Transplant immunological and cytological examinations of Standard conditioning/RIC 10/2 6/9 bronchoalveolar fluid, computed tomography and Source PB/BM 8/4 11/4 donor type pulmonary function tests. All the patients with acute match sibling 8 13 GVHD had grade II–IV disease (according to the unrelated 4 2 Glucksberg scale), and were refractory to corticos- GVH prophylaxis teroids (2-3 mg/kg/day of prednisone for a minimum CSA MTX 9 10 of 5 days associated with either cyclosporine or CSA MMF 2 1 cyclosporine + mycophenolate mofetil). All patients CSA 1 4 Previous acute GVHD 6 /15 with chronic GVHD presented an extensive form of - the disease resisting immunosuppressive therapy RIC: reduced intensity conditioning; CSA: cyclosporine A; MTX: methotrexate with associated corticosteroids given at a minimum (days 1, 3, 6); MMF: mycophenolate mofetil; PB: peripheral blood; dose of 2 mg/kg/day for at least 1 month. The results BM: bone marrow. of ECP treatment in both acute and chronic GVHD were evaluated as previously described.12 Complete response was defined as complete resolution of all cases with a hematocrit >5%, when the irradiation manifestations of chronic GVHD with discontinua- was 2.5 J/cm2). The final product was intravenously tion of the immunosuppressive drug. For skin infused in the patient within 3 hours after irradiation. involvement, a partial response was considered to Six courses were given during the first 3 weeks, then, have occurred when at least 50% of the skin involve- after clinical evaluation, ECP was stopped if there ment appeared to be non-inflammatory or fixed; a was complete response; in cases of partial response, complete response was defined as either the disap- maintenance therapy was one course per week until pearance of all lesions or the presence of fixed and complete response. In the case of no response, ECP pigmented lesions; in cases in which immunosup- was interrupted after six courses. Each patient’s pressive drugs were maintained, the response was blood count was obtained before apheresis and all considered as partial. Improvement of 50% in one products were tested: the quality control included organ involved was considered as a partial response. cell count and hematocrit. Evaluations were systematically scheduled for 1 month, 3 months and 6 months after the beginning of ECP. The patients’ characteristics are listed in Results Table 1. Acute GVHD ECP procedure For the patients with refractory acute GVHD, the Patients were treated according the Vilbert Lourma ECP was added to immunosuppressive treatment procedure, as previously described.16,17 Briefly, leuka- with cyclosporine and/or mycophenolate mofetil pheresis was performed using a Spectra cell separator and corticosteroids. All patients had a stable skin (Cobe, USA) with treatment of three whole blood response when evaluated after six courses of ECP, masses. Mononuclear cells were transferred to a bag except two patients in whom responses appeared to specially adapted for UVA irradiation (MacoPharma, be transient, noted as no response in Table 2A. These France) and 8-methoxypsoralen was added ex vivo. two non-responding patients developed rapidly pro- Thereafter, cells were UVA-irradiated at 2 J/cm2 (UV gressive, severe grade IV GVHD with skin, liver and matic irradiator, Vilbert Lourma, France), except in gut involvement, leading to death despite additional haematologica/the hematology journal | 2005; 90(8) | 1097 | F. Garban et al. treatment with anti-thymocyte globulins. Nine of the Table 2A. Organ involvement in patients with acute GVHD and clin- patients did not require a complementary immuno- ical responses. suppressive regimen. The others rapidly progressed and two died from liver failure (see above), one from Staging pre- ECP post ECP multiorgan failure with GVHD lesions. Cortico- steroids were stopped between 1 and 2 months after Skin ECP initiation in all responding patients. Among the Acute grade O 0 8 patients evaluable for chronic GVHD, three devel- Acute grade I-II 4 1 oped signs of chronic GVHD
Load more

Recommended publications
  • Extracorporeal Photopheresis for the Treatment of Refractory Chronic Graft-Versus-Host Disease
    Request for Medicare National Coverage Determination: Extracorporeal Photopheresis for the Treatment of Refractory Chronic Graft-Versus-Host Disease April 16, 2006 Submitted by: Therakos Inc. 437 Creamery Way Exton, PA 19341 Contact information: Dennis DeCola VP of Compliance and Scientific Affairs Tel: 610-280-1004 Fax: 610-280-1087 E-Mail: [email protected] Request for National Coverage Determination Extracorporeal Photopheresis for Refractory Chronic Graft-Versus-Host Disease April 16, 2006 Page 1 Statement of request Under the National Coverage Determination process, Therakos requests that CMS ex- pand its coverage of Extracorporeal photopheresis (ECP) to include extensive chronic graft-versus-host disease (cGVHD) that has failed to respond to corticosteroids and standard immunosuppressive drug therapy. Specifically, we propose coverage criteria that qualifying Medicare-eligible patients have documented extensive cGVHD that is re­ fractory or resistant to conventional immunosuppressive drug therapy, or are corticoster­ oid-dependent and require dose reduction to abrogate or diminish the risk of infectious or other complications related to high-dose corticosteroid and other immunosuppressive drug therapy. This application of photopheresis is (1) supported by an extensive publication record which documents both efficacy in achieving durable remissions and steroid- and drug- sparing benefit, (2) is widely used in clinical practice in the U.S., and (3) is almost uni­ versally covered by commercial U.S. insurers for the privately insured non-Medicare population. Description of the extracorporeal photopheresis procedure Extracorporeal photopheresis (ECP), also sometimes referred to as extracorporeal photo- chemotherapy, is a highly specialized procedure designed to induce apoptosis in ap­ proximately 10-15% of circulating T-lymphocytes and other leukocytes captured in the buffy coat phase of the patient’s blood.
    [Show full text]
  • Immunological Mechanisms of Extracorporeal Photopheresis in Cutaneous T Cell Lymphoma and Graft Versus Host Disease
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 12-2012 IMMUNOLOGICAL MECHANISMS OF EXTRACORPOREAL PHOTOPHERESIS IN CUTANEOUS T CELL LYMPHOMA AND GRAFT VERSUS HOST DISEASE Lisa Shiue Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Immunopathology Commons, Immunoprophylaxis and Therapy Commons, Medicine and Health Sciences Commons, and the Other Immunology and Infectious Disease Commons Recommended Citation Shiue, Lisa, "IMMUNOLOGICAL MECHANISMS OF EXTRACORPOREAL PHOTOPHERESIS IN CUTANEOUS T CELL LYMPHOMA AND GRAFT VERSUS HOST DISEASE" (2012). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 327. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/327 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. IMMUNOLOGICAL MECHANISMS OF EXTRACORPOREAL PHOTOPHERESIS IN CUTANEOUS T CELL LYMPHOMA AND GRAFT VERSUS HOST DISEASE by Lisa Harn-Ging Shiue, B.S. APPROVED: ________________________________________ Madeleine Duvic, M.D., Supervisory Professor _______________________________ Amin Alousi, M.D. ________________________________ Wei Cao, Ph.D. _________________________________ Dorothy Lewis, Ph.D. ______________________________ Greg Lizee, Ph.D.
    [Show full text]
  • ECP) (ECP) • Review ECP Side-Effects, Patient Education and Hazardous Drug Aspects
    12/10/2014 Objectives Acute Graft-Versus-Host Disease • Explain the mechanics of extracorporeal and Extracorporeal Photopheresis photopheresis (ECP) (ECP) • Review ECP side-effects, patient education and hazardous drug aspects LCDR Tracey Chinn, RN, BSN, MPM • Discuss therapy impact to the Clinical Assistant to the Chief, ETIB, NCI inpatient/outpatient Nurse Technical Considerations: Technical Considerations Apheresis Instrument • Cellex (Therakos, Inc.) ▫ Single and double venous access • Uvar XTS (Therakos, Inc.) ▫ Single venous-access only ▫ Current NIH instrument ECP: The Mechanics Technical Considerations: Venous Access 1. Blood is drawn and separated thru centrifugation; WBC are separated and • Apheresis specialist should perform venous collected assessment and make recommendations 2. Plasma and RBCs returned to patient 3. Methoxsalen (Uvadex®) added to the WBC • Peripheral Venous Access 4. Medicated WBC cells exposed to UVA light, ▫ Average needle size = 17-18 gauge which activates the medication ▫ Needle is placed and removed at time of therapy 5. Treated WBC returned to patient; prompt an immune response 1 12/10/2014 Technical Considerations: Technical Considerations: Venous Access Extracorporeal Volume (ECV) • CVAD Access • ECV = Safe mL/whole blood can be taken out of ▫ Typical catheter/size = 9.6 french single-lumen body at one period of time Hickman ▫ NURS – CVAD Flushing Guidelines: “Dialysis/Apheresis –All Purpose Use” • ECV < 15% TBV (Total Blood Volume) ▫ Preference = Use ONLY for therapy • ECV is directly related to: ▫ Safety / Bowl size / Blood prime (< 20 kg) ▫ # Cycles performed = # WBC treated Technical Considerations: Technical Considerations: Extracorporeal Volume (ECV) Extracorporeal Volume (ECV) • Average adult total blood volume = 7- 8% of • Example: body weight ▫ 55 kg (weight) x 70 mL/kg = 3850 mL (TBV) • TBV = patient weight (kg) x body build (mL/kg) ▫ 3850 mL (TBV) x 0.15 = 577 mL (ECV) ▫ Normal build = 70 mL/kg of body weight ▫ Varies based on body build (i.e.
    [Show full text]
  • Extracorporeal Photochemotherapy) Reference Number: HNCA.CP.MP.291 Effective Date: 09/06 Coding Implications Last Review Date: 03/21 Revision Log
    Clinical Policy: Photopheresis (Extracorporeal Photochemotherapy) Reference Number: HNCA.CP.MP.291 Effective Date: 09/06 Coding Implications Last Review Date: 03/21 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Extracorporeal photochemotherapy (ECP), also called photopheresis, is a cell-based immunomodulatory therapy that involves collecting leukocytes from peripheral blood. These cells are exposed to a photosensitizing agent, 8-methoxypsoralen, and are then treated with ultraviolet radiation, after which they are re-infused. This procedure, which results in crosslinking of pyrimidine bases in DNA, produces massive apoptosis of the treated cells. The mechanism of action has not been fully elucidated, however, it is likely that photopheresis activates antigen-presenting cells, such that tumor-related antigens are more readily presented to cytoxic T cells. Policy/Criteria I. It is the policy of Health Net of California that extracorporeal photochemotherapy/photopheresis is medically necessary for the treatment of any of the following: A. Advanced or refractory erythrodermic variants of cutaneous T-cell lymphoma (e.g., mycosis fungoides, Sézary’s syndrome); B. Treatment or prevention of acute or chronic graft-versus-host disease refractory to standard immunosuppressive therapy; C. Heart or heart-lung transplant rejection when rejection episodes are refractory to high- dose steroids plus two or more of the following, unless contraindicated: 1. Cyclosporine; 2. Azathioprine; 3. Methotrexate; 4. Polyclonal and monoclonal antilymphocyte agents (e.g., antilymphocyte globulin ALG], antithymocyte globulin [ATG], OKT3 [monoclonal T-cell antibody]); D. Lung transplant rejection in individuals who are refractory to or intolerant of standard therapy. II.
    [Show full text]
  • Current Research of Extracorporeal Photopheresis and Future
    Extracorporeal Photopheresis are then dispatched to the infected site. For example, the foliative dermatitis, and adenopathy (inflammation of the Current Research of Extracorporeal Photopheresis and Th-1 response is mediated by CD4+ helper T-cells and lymph nodes). Patients with SS do not have a good prog- Future Applications CD8+ T-5 cells that secrete IFN-γ, IL-2, and IL-12 to fight nosis; there is an average survival rate of only 3 years against viruses. The CD4+ helper cells then “help” to in- (Scarisbrick, et al, 2001). SS patients have been found to Chaim Lederer voke a cytotoxic attack against the virus, mainly through have a high rate of Staph colonization. Secondary and hos- CD8+ cytotoxic T-cells (Steinman, Hemmi, 2006) pital acquired infections, most often from Staphylococcus Abstract (Kadowaki, 2007) . aureus (Staph) sepsis due to an impaired immune system, breaks in the skin and use of catheters are particularly fatal Photopheresis, also known as Extracorporeal Photopheresis (ECP) is making inroads in treatment of previously untreata- Located in the immune system, T-regulatory cells in SS patients. The cause of SS is unknown and the diag- ble diseases. As the medical world has delved deeper into, Although the mechanisms of photopheresis are largely un- (T-regs) regulate a wide variety of immune cells such as nosis is very difficult due to its similarities to other skin ail- known, increasingly detailed studies have proven its efficacy. The lack of side effects has made photopheresis an ideal CD4+, CD8+, B-cells, natural killer T-cells, and antigen pre- ments. It was originally believed that SS was derived from option for patients.
    [Show full text]
  • The Need for Individualized Procedures in ECP, the European Perspective!
    The Need for Individualized Procedures in ECP, the European Perspective! Volker Witt, MD St. Anna Kinderspital, Vienna, Austria ECP = extrcorporeal photopheresis 1 2 3 4 15.01.2015 2 What is ECP? STEPS OF THE PROCESS • Harvesting Leukocytes • Preparing a buffy coat • Adding a Photosensitizer • Transferring in a irradiation disposable • Irradiating a “buffy coat” • Retransfusion to the patient What is ECP? STEPS OF THE PROCESS • Harvesting Leukocytes • Apheresis • Preparing a buffy coat • Inline systems • Offline systems • Adding a Photosensitizer • To draw peripheral blood • Transferring in a irradiation disposable • Irradiating a “buffy coat” • Retransfusion to the patient What is ECP? STEPS OF THE PROCESS • Harvesting Leukocytes • Directly from the Apheresis • Preparing a buffy coat device • Adding a Photosensitizer • Diluted by plasma • Transferring in a irradiation • Diluted by saline solution disposable • Hematocrit • Irradiating a “buffy coat” • Retransfusion to the patient What is ECP? STEPS OF THE PROCESS • Harvesting Leukocytes • 8-MOP • Preparing a buffy coat • Final concentration (?) • Adding a Photosensitizer • Transferring in a irradiation disposable • Irradiating a “buffy coat” • Retransfusion to the patient What is ECP? STEPS OF THE PROCESS • Harvesting Leukocytes • Chamber • Preparing a buffy coat • Bag • Adding a Photosensitizer • Transferring in a irradiation disposable • Irradiating a “buffy coat” • Retransfusion to the patient What is ECP? STEPS OF THE PROCESS • Harvesting Leukocytes • In a pivoting a bag • Preparing
    [Show full text]
  • Guidelines for Use of Extracorporeal Photopheresis in Acute Graft-Versus-Host Disease (GVHD) Bryan A
    Washington University School of Medicine Digital Commons@Becker Kidneycentric Kidneycentric 12-2015 Guidelines for use of extracorporeal photopheresis in acute graft-versus-host disease (GVHD) Bryan A. Sisk Washington University School of Medicine in St. Louis Follow this and additional works at: http://digitalcommons.wustl.edu/kidneycentric_all Recommended Citation Sisk, Bryan A., "Guidelines for use of extracorporeal photopheresis in acute graft-versus-host disease (GVHD)" (2015). Kidneycentric. Paper 11. http://digitalcommons.wustl.edu/kidneycentric_all/11 This Article is brought to you for free and open access by the Kidneycentric at Digital Commons@Becker. It has been accepted for inclusion in Kidneycentric by an authorized administrator of Digital Commons@Becker. For more information, please contact [email protected]. Guidelines for Use of Extracorporeal Photopheresis in Acute Graft-Versus-Host Disease (GVHD) Bryan Sisk, MD 7/18/2015 History: The first investigational study on the use of extracorporeal photopheresis (ECP) was published in 1987, and focused on treatment of cutaneous T-cell lymphoma.1 This study led the FDA to approve of photopheresis. Although T-cell lymphoma is the only FDA approved indication for photopheresis its therapeutic use has expanded to a number of other disease processes, most notably acute and chronic graft versus host disease (GVHD). Photopheresis Procedure: ECP is a leukapheresis-based therapy. Whole blood is processed outside of the body in the following way: whole blood is drawn from a catheter placed in a central vein; using centrifugation the different constituents of blood are separated based upon density i.e. white blood cells (WBC) separate into the buffy coat which can distinguished from red blood cells (RBCs) and plasma.2 The RBCs and plasma are returned to the patient, but the buffy coat containing the WBCs is isolated (it should be noted that only 5-10% of the patients WBCs are typically captured during the procedure).
    [Show full text]
  • Extracorporeal Photopheresis Practice Patterns: an International Survey by the ASFA ECP Subcommittee
    Received: 2 May 2016 | Revised: 30 June 2016 | Accepted: 1 July 2016 DOI 10.1002/jca.21486 RESEARCH ARTICLE Extracorporeal photopheresis practice patterns: An international survey by the ASFA ECP subcommittee Nancy M. Dunbar1 | Jay S. Raval2 | Andrew Johnson3 | Cori M. Abikoff4 | Jill Adamski5 | Laura L. Cooling6 | Brenda Grossman7 | Haewon C. Kim8 | Marisa B. Marques9 | Shanna Morgan3,10,11 | Amy E. Schmidt12 | Steven R. Sloan13 | Leon L. Su14 | Zbigniew M. Szczepiorkowski1,17 | F. Bernadette West4 | Edward Wong15 | Jennifer Schneiderman16 1 Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Abstract Center, Lebanon NH Background: Although many apheresis centers offer extracorporeal photopheresis 2 Department of Pathology and Laboratory Medicine, University of North Carolina, (ECP), little is known about current treatment practices. Chapel Hill, NC Methods: An electronic survey was distributed to assess ECP practice 3 Department of Laboratory Medicine and Pathology, University of Minnesota, internationally. Minneapolis, MN Results: Of 251 responses, 137 met criteria for analysis. Most respondents were 4 Department of Pediatrics, New York from North America (80%). Nurses perform ECP at most centers (84%) and the Medical College, Valhalla, NY majority of centers treat adults only (52%). Most centers treat fewer than 50 patients/ 5 Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ year (83%) and perform fewer than 300 procedures/year (70%). Closed system 6 Department of Pathology, University of devices (XTS and/or Cellex) are used to perform ECP at most centers (96%). The Michigan School of Medicine, Ann Arbor, most common indications for ECP are acute/chronic skin graft versus host disease MI (89%) and cutaneous T-cell lymphoma (63%).
    [Show full text]
  • Cryopreservation As a Way to Maintain Extracorporeal Photopheresis Regimen for Gvhd Treatment While Circumventing Patient Temporary Inability to Undergo Apheresis
    Bone Marrow Transplantation (2017) 52, 167–170 © 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 0268-3369/17 www.nature.com/bmt LETTER TO THE EDITOR Cryopreservation as a way to maintain extracorporeal photopheresis regimen for GvHD treatment while circumventing patient temporary inability to undergo apheresis Bone Marrow Transplantation (2017) 52, 167–170; doi:10.1038/ Nucleated cells were quantified using the pocH-100i device bmt.2016.240; published online 19 September 2016 (Sysmex, Villepinte, France). Cell viability was analyzed by flow cytometry using 7-aminoActinomycin D. CD3+ and CD14+ cells were quantified by FACS analysis, only in the Nancy center. Extracorporeal photopheresis (ECP) is a safe treatment in patients In both centers, the same treatment regimen was used with at with mild acute or chronic GvHD.1–3 However, its clinical use is least 3 ECP (fresh or ‘cryo-ECP’) per week for acute GvHD, and 1 sometimes limited by logistical problems that compromise or 2 ECP per week (depending on GvHD grade) for chronic or late repeated aphereses, especially venous access failure. acute GVHD, until clinical improvement. Merlin et al.4 previously concluded that cryopreservation The clinical severity of acute GvHD was determined as defined 5 before irradiation did not impair WBC functional capabilities. in the 1994 consensus conference criteria. The severity of chronic The hematopoietic stem cell transplantation (HSCT) centers of GvHD was determined as per the 2005 National Institutes of 6 Nancy and Clermont-Ferrand (CF) University Hospitals Health (NIH) consensus guidelines. Response was retrospectively investigated the use of frozen and thawed WBC (FTWBC, assessed at 1, 3 and 6 months in all patients.
    [Show full text]
  • ECP) in the Treatment of Chronic Graft- Versus-Host Disease (GVHD
    Bone Marrow Transplantation, (1999) 23, 881–887 1999 Stockton Press All rights reserved 0268–3369/99 $12.00 http://www.stockton-press.co.uk/bmt Extracorporeal photopheresis (ECP) in the treatment of chronic graft- versus-host disease (GVHD) FJ Child1, R Ratnavel1, P Watkins1, D Samson2, J Apperley2, J Ball3, P Taylor3 and R Russell-Jones1 1Skin Tumour Unit, St John’s Institute of Dermatology, St Thomas’ Hospital, London; 2Department of Haematology, Hammersmith Hospital, London; and 3Department of Haematology, Rotherham District General Hospital, Rotherham, UK Summary: morbidity and mortality. Acute GVHD affects 40–50% of allogeneic stem cell transplant recipients and chronic The aim of our study was to assess the efficacy of extra- GVHD affects 30–50% of those surviving the acute phase corporeal photopheresis (ECP) in chronic graft-versus- of transplantation.1,2 host disease (GVHD). Eleven patients with chronic Prevention of GVHD is important because treatment of cutaneous GVHD were studied. Four had mucosal established disease is often unsatisfactory. Measures such involvement and five had pulmonary involvement. All as pre-transplant T cell depletion and immunosuppression had failed to improve on first- and second-line therapy. with methotrexate, cyclosporin A and prednisolone are Three patients received ECP alone; the remainder con- routinely undertaken. tinued to receive steroids and/or immunosuppressive Chronic GVHD may be limited to localised skin involve- therapy. Patients received ECP twice monthly for 4 ment and liver dysfunction, or the disease may be more months and then once monthly for 3 months. They were extensive with generalised skin involvement and additional evaluated by serial skin scores, mucosal and skin pho- organ involvement.
    [Show full text]
  • The Role of Photopheresis in the Treatment of Bronchiolitis Obliterans Syndrome
    The Role of Photopheresis in the Treatment of Bronchiolitis Obliterans Syndrome Selim M. Arcasoy, M.D. Medical Program Director Lung Transplantation Program NewYork-Presbyterian Hospital Columbia University Medical Center New York, NY Terminology/Definitions • OB=BO: Obliterative bronchiolitis or bronchiolitis obliterans • Histopathologic term used to describe the finding of fibrous obliteration of small airways after LTx • BOS: Bronchiolitis obliterans syndrome • Clinical/physiologic definition of chronic lung allograft dysfunction caused by OB and characterized by progressive airflow limitation • Term originally proposed in 1993 and revised in 2002 Bronchiolitis Obliterans Syndrome Clinical Impact Very common and deadly • Cumulative risk of 50-80% between 5 and 10 years after lung transplantation • Leading cause of long-term mortality • Directly or indirectly accounts for at least 30 to 50% of deaths after third post-operative year • Less than 40% survival at 5 years after its onset Injury to airway epithelium Normal Alloimmune or non-alloimmune Pathogenesis of OB (rejection, infection, aspiration, ischemia) Inflammatory response Vascular changes Innate and adaptive immune response (PMN, macrophage, DC, T- and B-lymphocytes) Final common pathway IL-1, IL-2, IL-6, IL-8, IL-12, Repair response TNF-α, MCP-1, complement, Fibroblast proliferation IFN-γ, RANTES, ROS, NO, EC matrix deposition peroxides, leukotrienes TGF-ß,PDGF, IGF, FGF, ET-1 Mechanisms and Therapy of OB After Lung Tx Adapted from Nicod. Proc Am Thorac Soc 2006;3:444 Irritants/
    [Show full text]
  • Extracorporeal Photopheresis
    Medical Coverage Policy Effective Date ............................................05/15/2021 Next Review Date ......................................05/15/2022 Coverage Policy Number .................................. 0320 Extracorporeal Photopheresis Table of Contents Related Coverage Resources Overview .............................................................. 1 Heart, Lung and Heart-Lung Transplantation Coverage Policy ................................................... 1 Plasmapheresis General Background ............................................ 2 Medicare Coverage Determinations .................... 4 Coding/Billing Information .................................... 5 References .......................................................... 5 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For
    [Show full text]